Chamberlain fought off Hill & Knowlton, Chandler Chicco and incumbent Fleishman-Hillard, which has handled the account for the past six years, to win the business.
The pitch was overseen by Rebecca Fisher-Pollard in the Novartis pharma comms team.
The business is expected to be transferred immediately.
Galvus is an oral anti-diabetic drug that helps to reduce hyperglycemia (high blood sugar) in Type 2 diabetics.
Type 2 diabetes is a condition that affects more than two million people in the UK and occurs when the pancreas does not manufacture enough insulin to meet a person’s needs, or the insulin is not metabolised effectively.
Chamberlain PR referred all calls to the client. Novartis said that a decision on the account would be made in ‘due course’.
Chamberlain has had a resurgence since the appointment of former Cohn & Wolfe senior director Mark Cater as managing director in March.
Cater was previously C&W regional director for the EMEA region, a role he took in 2008. Prior to that, he was head of GCI before it merged with C&W.
Since the beginning of the year, Chamberlain has picked up accounts including drugs firm Mundipharma, to handle company-wide comms.
Chamberlain launched a London office in 2008, which was initially headed by MD Amanda Moulson.
However, she stepped down after just a year and moved to Ketchum in March 2009, taking the post of associate director in the senior healthcare team.
